| Budget Amount *help |
¥4,810,000 (Direct Cost: ¥3,700,000、Indirect Cost: ¥1,110,000)
Fiscal Year 2017: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2016: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2015: ¥1,950,000 (Direct Cost: ¥1,500,000、Indirect Cost: ¥450,000)
|
|---|
| Outline of Final Research Achievements |
Accumulation of genetic mutations is critical for lymphomatogenesis, disease progression and sensitivity to targeting therapeutics in malignant lymphoma (ML). In this analysis, peripheral blood cell-free DNA (cfDNA) was longitudinally analyzed to reveal correlation with clinical features and to detect tumor specific genetic alterations. Especially in intravascular large B-cell lymphoma, those tumor cells are hardly obtained from biopsy sample, cfDNA was an alternative tumor DNA source to detect specific genetic alterations in comprehensive genetic analyses. Genetic analyses using cfDNA may become an alternative powerful strategy to detect tumor specific genetic abnormalities not only for diagnosis but also longitudinal analyses to predict sensitivity to molecular targeting drugs, even in patients whose tumor cells cannot be obtained easily during their clinical courses.
|
